Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients

Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice

(2012) Prasanta K. Dash et al.   AIDS

Nanoparticle-based combination therapy toward overcoming drug resistance in cancer

(2012) Che-Ming Jack Hu et al.   BIOCHEMICAL PHARMACOLOGY

Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells

(2012) Georgette Kanmogne et al.   International Journal of Nanomedicine

Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1–Infected Human Peripheral Blood Lymphocyte–Reconstituted Mice

(2012) Upal Roy et al.   JOURNAL OF INFECTIOUS DISEASES

Recent progress in nanotechnology for cancer therapy

(2012) Mu-Fei Tang et al.   Chinese Journal of Cancer

Public optimism towards nanomedicine

(2011) Massimo Bottini et al.   International Journal of Nanomedicine

The Critical Need for Alternative Antiretroviral Formulations, and Obstacles to Their Development

(2011) Susan Swindells et al.   JOURNAL OF INFECTIOUS DISEASES

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

(2010) Frederick L Altice et al.   LANCET

HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals

(2010) D. Trono et al.   SCIENCE

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

(2009) Lieven Baert et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS